Sutro Biopharma(US:STRO) ZACKS·2025-11-07 00:26Core Insights - Sutro Biopharma, Inc. reported a quarterly loss of $0.67 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, marking an earnings surprise of -59.52% [1] - The company generated revenues of $9.69 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 16.52% and showing an increase from $8.52 million year-over-year [2] - Sutro Biopharma's stock has declined approximately 46.5% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, Sutro Biopharma has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $8.89 million, and for the current fiscal year, it is -$1.84 on revenues of $96.57 million [7] Industry Context - Sutro Biopharma operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries [8] - The performance of Sutro Biopharma's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones by a significant margin [8]